Method for reducing tissue damage associated with ischemia-reper

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514 2, 514 8, A61K 3817, A61K 3818

Patent

active

060778237

ABSTRACT:
The present invention is directed to methods and compositions for alleviating tissue destructive effects associated with the inflammatory response to tissue injury in a mammal. The methods and compositions include administering a therapeutically effective concentration of a morphogen or morphogen-stimulating agent sufficient to alleviate immune cell-mediated tissue destruction.

REFERENCES:
patent: 4806523 (1989-02-01), Bentz et al.
patent: 4877864 (1989-10-01), Wang et al.
patent: 4968590 (1990-11-01), Kuberasampath et al.
patent: 4971952 (1990-11-01), Bentz et al.
patent: 4975526 (1990-12-01), Kuberasampath et al.
patent: 5002965 (1991-03-01), Ramwell et al.
patent: 5011691 (1991-04-01), Oppermann et al.
patent: 5013649 (1991-05-01), Wang et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5106626 (1992-04-01), Parsons et al.
patent: 5108753 (1992-04-01), Kuberasampath
patent: 5118791 (1992-06-01), Burnier et al.
patent: 5135915 (1992-08-01), Czarniecki et al.
patent: 5141905 (1992-08-01), Rosen et al.
patent: 5202311 (1993-04-01), Folkman et al.
patent: 5221734 (1993-06-01), Burk et al.
patent: 5972884 (1999-10-01), Cohen et al.
Behringer et al., Nature, 345:167-170 (1990).
Cate et al., Cell, 45:685-698 (1986).
Celeste et al., PNAS, 87:9843-9847 (1990).
Green et al., Nature, 347:391-394 (1990).
Kuberasampath et al., J. Biol. Chem., 265:13198-13205 (1990).
Lee, Molecular Endocrinology, 90:1034-1040 (1990).
Lee, PNAS, 88: 4250-4254 (1991).
Lyons et al., PNAS, 86:4554-4558 (1989).
Lyons et al., Genes & Development, 3:1657-1668 (1989).
Mason et al., Nature, 318:659-663 (1985).
Mason et al., Mol. Endocrinology, 3:1352-1358 (1989).
Miller et al., Cancer Research, 42:2589-3594 (1987).
Ozkaynak et al., Embo J., 9:2085-2093 (1990).
Ozkaynak et al., Biochem. Biophys. Res. Comm., 179:116-123 (1991).
Padgett et al., Nature, 325:81-34 (1987).
Panganiban et al., Mol. and Cell. Biol., 10:2669-2677 (1990).
Sampath et al., PNAS, 80:6591-6595 (1983).
Schbert et al., Nature, 344:868-870 (1990).
Smith et al., Nature, 345:729-731 (1990).
Sokol et al., Science, 249:561-563 (1990).
Wang et al., PNAS, 87:2220-2224 (1990).
Wang et al., PNAS, 85:9484-9488 (1988).
Weeks, Cell, 51:861-867 (1987).
Wharton et al., PNAS, 88:9214-9218 (1991).
Wozney et al., Science, 242:1528-1534 (1988).
Yannas, Angew. Chem. Int. Ed. Engl., 29:20-35 (1990).
Lefer et al., Science, vol. 249, No. 4964, pp. 61-64, Jul. 6, 1990.
Kuruvilla et al., Proc. Natl. Acad. Sci. USA, vol. 88, No. 7, pp. 2918-2921, Apr. 1991.
Wozney et al. (1990), "Growth Factors Influencing Bone Development," 13 J. Cell Sci. Suppl. 149-156.
Celeste et al. (1990), "Identification of Transforming Growth Factor .beta. Family Members Present in Bone-Inductive Protein Purified From Bovine Bone," 87 PNAS 9843-9847.
Takuwa et al. (1991), "Bone Morphogenetic Protein-2 Stimulates Alkaline Phosphatase Activity and Collagen Synthesis in Cultured Osteoblastic Cells, MC3T3-E1," 174 Biochem. Biophys. Res. Comm. 1:96-101.
Yamaguchi et al. (1991), "Recombinant Human Bone Morphogenetic Protein-2 Stimulates Osteoblastic Maturation and Inhibits Myogenic Differentiation In Vitro," 113 J. Cell Biol. 3:681-687.
D'Allesandro et al. (1991), Abstract Q-105 J. Cell. Biochem.
Israel et al. (1991), Abstract Q-111 J. Cell. Biochem.
Thies et al. (1992), "Recombinant Human Bone Morphogenetic Protein-2 Induces Osteoblastic Differentiation in W-20-17 Stromal Cells," 130 Endocrinology 3:1318-1324.
Wozney et al. (1992), "The Bone Morphogenetic Protein Family and Osteogenesis," 32 Mol. Reprod. Dev. 2:160-167.
Rogers et al. (1992), "Bone Morphogenetic Proteins-2 and -4 are Involved In The Retinoic Acid-Induced Differentiation of Embryonal Carcinoma Cells," 3 Mol. Biol. Cell 2:189-196.
Wozney et al, ; Celeste et al.; Rosen et al. (1992), Abstracts 76(WO26), 100(W502) and 103(W513) J. Cell Biochem, Suppl. 16 Part F.
Israel et al. (1992), "Expression and Characterization of Bone Morphogenetic Protein-2 in Chinese Hamster Ovary Cells," 7 Growth Factors 139-150.
Padgett et al. (1993), "Human BMP Sequences Can Confer Normal Dorsal-Ventral Patterning in the Drosophila Embryo," 90 PNAS 2905-2909.
Wozney et al. (1988), "Novel Regulators of Bone Formation: Molecular Clones and Activities," 242 Science 1528-1534.
Wang et al. (1988), "Purification and Characterization of Other Distinct Bone-Inducing Factors,";0 85 PNAS 9484-9488.
Rosen et al. (1989), "Purification and Molecular Cloning of a Novel Group of BMPS and Localization of BMP MRNA In Developing Bone," 20 Connect. Tissue Res. 1-4:313-319.
Wozney et al. (1990), "Bone Morphogenic Proteins," 1 Prog. In Growth Factor Res. 267-280.
Wang et al. (1990), "Recombinant Human Bone Morphogenetic Protein Induces Bone Formation," 87 PNAS 2220-2224.
Rosen et al.; Celeste et al. (1990), 2 Abstracts J. Cell Biochem, Suppl. 14 Part E, 004:33; 54:105.
Katagiri et al. (1990), "The Non-Osteogenic Mouse Pluripotent Cell Line, C3H10T1/2 is Induced to Differentiate Into Osteoblastic Cells by Recombinant Human Bone Morphogenetic Protein-2," 172 Biochem. Biophys. Res. 1:295-299.
Hammond et al. Can J. Physiol. Pharmacol. 63:173-187, 1985.
Bowie et al. Science 247:1306-1310, 1990.
Sampath et al. (1983), "Homology of Bone-Inductive Proteins From Human, Monkey, Bovine, and Rat Extracellular Matrix," 80 Proc. Nat'l. Acad. Sci. USA 6591-6595.
Bentz et al. (1987), "Cartilage Induction and Differentiation: The Role of Bone Derived Cartilage Inducing Factor (CIF-A)," Dev. & Diseases of Cartil. & Bone Matrix 137-147.
Ruscetti et al. (1991), "Transforming Growth Factor-.beta. And The Immune System," 3 Prog. Growth Factor Res. 159-175.
Sporn et al. (1992), "Transforming Growth Factor-.beta.: Recent Progress and New Challenges," 119 J. Cell Biol. 1017-1021.
Gross et al. (1993), "Transforming Growth Factor-.beta.1 Reduces Infarct Size After Experimental Cerebral Ischemia in a Rabbit Model," 24 Stroke 558-562.
Reddi et al. (1993), "Initiation and Promotion of Bone Differentiation by Bone Morphogenetic Proteins," 8 J. Bone Min. Res. 2:S499-S502.
Sampath et al. (1994), "Structure, Function, and Orthopedic Applications of Osteogenic Protein-1 (OP-1)," Complications in Orthop. 101-107.
Deininger et al. (1995), "Detection of Two Transforming Growth Factor-.beta.-Related Morphogens, Bone Morphogenetic Proteins -4 and -5, in RNA of Multiple Sclerosis and Creutzfeldt-Jakob Disease Lesions," 90 Acta Neuropathol. 76-79.
Schluesener et al. (1995), "Immunolocalization of BMP-6, a Novel TGF-.beta.-Related Cytokine, in Normal and Atherosclerotic Smooth Muscle Cells," 113 Atherosclerosis 153-156.
Schluesener et al. (1995), "Immunolocalization of vgr (BMP-6, DVR-6), a TGF-.beta.-Related Cytokine, to Schwann Cells of the Rat Peripheral Nervous System: Expression Patterns Are Not Modulated by Autoimmune Disease," 13 GLIA 75-78.
Noda et al. Endocrinology 124:2991-2994, 1989.
Joyce et al. Annals of the New York Academy of Sciences 593:107-123, 1990.
Beck et al. J. Bone Min. Res. 6: 1257-1265, 1991.
Puolakkainen et al. J. Surg. Res. 58:321-329, 1995.
Gennaro (1990) Remington's Pharmaceutical Sciences (Mack Pubs., N.Y.).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for reducing tissue damage associated with ischemia-reper does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for reducing tissue damage associated with ischemia-reper, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing tissue damage associated with ischemia-reper will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1852407

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.